Efficacy and Safety of PRaG Therapy in Elderly Patients with Advanced Malignant Tumors: A Prospective, Multicenter Clinical Study Protocol (PRaG 9.0 Study)

The protocol addresses the underrepresentation of very old adults in immunotherapy trials.

Technology in cancer research & treatment · Nov 27, 2025
Original authors: Xiangrong Zhao, MengMeng Yang, Junjun Zhang, Yuehong Kong, Meiling Xu, Rongzheng Chen, Qian Yin, Sumeng Wang, Guangqiang Chen, Pengfei Xing, Liyuan Zhang

Study protocol: planned research, not a report of completed treatment outcomes.

Who was studied?

Planned enrollment: 29 patients aged 75 years or older with advanced solid tumors.

What does the publication report?

A prospective, single-arm phase II study is planned. The enrollment target is not a completed patient count.

Safety findings

Prospective safety evaluation is planned; no observed event rates are reported in this protocol.

How should we interpret it?

This is a study protocol, not a report of treatment results. Planned enrollment and endpoints are not observed outcomes.

Read the original source

This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.

Efficacy and Safety of PRaG Therapy in Elderly Patients with Advanced Malignant Tumors: A Prospective, Multicenter Clinical Study Protocol (PRaG 9.0 Study) · DOI: 10.1177/15330338251400412 · PMID: 41308040

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.